RNS60
RNS60 is a pharmaceutical drug with 12 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 8 completed trials
Phase Distribution
Phase Distribution
5
Early Stage
7
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
66.7%
8 of 12 finished
33.3%
4 ended early
0
trials recruiting
12
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Nebulized RNS60 for the Treatment of Amyotrophic Lateral Sclerosis
Safety of RNS60 in Large Vessel Occlusion Stroke Patients Undergoing Endovascular Thrombectomy
The Effect of RNS60 on ALS Biomarkers
A Pilot Study of RNS60 in Amyotrophic Lateral Sclerosis (ALS)
Effect of RNS60 on the Late Phase Asthmatic Response to Allergen Challenge
Clinical Trials (12)
Nebulized RNS60 for the Treatment of Amyotrophic Lateral Sclerosis
Safety of RNS60 in Large Vessel Occlusion Stroke Patients Undergoing Endovascular Thrombectomy
The Effect of RNS60 on ALS Biomarkers
A Pilot Study of RNS60 in Amyotrophic Lateral Sclerosis (ALS)
Effect of RNS60 on the Late Phase Asthmatic Response to Allergen Challenge
Pilot Study of RNS60 in Allergen-induced Bronchoconstriction
Systemic Bioactivity of Inhaled Nebulized RNS60
Study of RNS60 on Pain and Function After Knee Anterior Cruciate Ligament Surgery
Study of RNS60 on Pain and Function After Hip Labral Repair
Study of Inhaled RNS60 in Combination With Budesonide to Treat Mild to Moderate Asthma
Safety Study of Nebulized RNS60 to Treat Asthma.
Safety and Tolerability of RNS60 Given by IV to Healthy Subjects
All 12 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 12